Chart: How does CSL Limited make its money?

How does big bio-tech company CSL Limited (ASX: CSL) really make its money?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CSL Limited (ASX: CSL) really is one of the most remarkable companies listed on the ASX.

The company is a case-study in the relentless value creation that can come from pricing power and long-term shareholders have seen their wealth compound at incredible rates of return.

But how does CSL Limited really make its money?

CSL's highly specialised products can be sorted into five product categories:

Source: compiled from CSL 2019 Annual Report

Immunoglobulins (42%)

These are antibodies used by the immune system to protect us against illness. CSL's products in this category, including Hizentra, are used to treat and prevent infections and to treat autoimmune diseases.

People often need these products if they are born without the immunities and antibodies they need, known as Primary Immunodeficiency. According to research in the Journal of Molecular Diagnostics, this impacts 1-in-500 people in the United States.

Other/Specialty products (19%)

This category includes a range of products like Kcentra, which helps blood clotting in patients that need urgent surgery but are taking the blood thinner Warfarin, which prevents blood clots.

Another example is Berinert, which treats the rare Hereditary Angioedema condition. This is the lack of a certain blood protein which can cause painful and dangerous swelling.

Seqirus (14%)

Seqirus is easier to understand, it's CSL's influenza vaccines business, researching and manufacturing vaccines. It is one of the largest influenza vaccine providers in the world and a growing part of the business, with revenue in the 2019 financial year up 12%.

Haemophilia products (12%)

These products help blood clotting and include products to treat Haemophilia A, B and other acute bleeding disorders. The products also go by the delightful term "plasma-derived coagulation products".

Albumin (14%)

Albumin is the most common type of protein found in our blood plasma and its role is to stabilise blood pressure. CSL's Albumin products help to restore blood volume and pressure in patients after trauma or surgery. It is also used for treating burns.

Foolish takeaway

The products CSL sells are well regarded and protected by patents which provide a strong competitive advantage.

If CSL continues to manage the risks that come with manufacturing biotech products I would expect it to continue growing at high rates of returns for years to come. It is one of very few companies I would be willing to pay a premium price to own.

Regan Pearson has no position in any of the stocks mentioned.

You can follow him on Twitter @Regan_Invests.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

1 ASX healthcare stock that looks severely undervalued

I think this stock looks too cheap to miss.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Own Medibank shares? Here's why it's a rewarding day for you

Shareholders are getting a healthy boost today.

Read more »

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »